Source: Annual Congress 2003 - Issues surrounding drug delivery
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Singh, P. Gilchrist, C. Niederlaender, B. Haeberlin (Basel, Switzerland). In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates. Eur Respir J 2003; 22: Suppl. 45, 2984

Member's Comments

No comment yet.

Related content which might interest you: In vitro performance characteristics of a novel multi-dose dry powder inhaler Airmax™ at different inspiratory flow rates Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002 In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 In vitro testing of two budesonide dry powder inhalers at different flow rates Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001 Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers Source: Eur Respir J 2001; 18: 780-783 Year: 2001 Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients Source: Annual Congress 2012 - Asthma management Year: 2012 Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003 Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs) Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001 Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002 Flow-dependent performance of several formoterol dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006 Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Peak inspiratory flow in COPD: implications for the use of dry powder inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001